FDA Plans to Use AI to Cut Drug Trial Timelines by Months or Years
The FDA is reportedly preparing to deploy AI tools aimed at significantly accelerating drug trial review processes, a potentially transformative move for pharmaceutical development.
Subscribe to unlock all stories
Get full access to The Singularity Ledger, archive included.
Cancel anytime. Payments powered by Stripe.